- Home
- ATCX vs CUE Comparison
ATCX vs CUE Comparison
Compare ATCX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | CUE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Brazil | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 27.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATCX | CUE |
|---|---|---|
| Price | $7.10 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 70.9K | ★ 355.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $5.32 | $0.23 |
| 52 Week High | $14.01 | $1.17 |
Technical Indicators
Market Signals| Indicator | ATCX | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 44.28 |
| Support Level | $5.93 | $0.28 |
| Resistance Level | $14.01 | $0.36 |
| Average True Range (ATR) | 0.79 | 0.02 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 70.42 | 38.58 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corporation, is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.